Ftse Mib
38.621,33
-0,41%
DAX
23.008,94
-1,87%
S&P 500
5.765,64
0,47%
NASDAQ
18.162,72
0,52%
Bitcoin
88.053,22
-2,09%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mirum Pharmaceuticals Inc (MIRM) Mirum Pharmaceuticals Inc (MIRM) Notizie

MIRM

Mirum Pharmaceuticals (MIRM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MIRM
DataOraFonteTitoloSimboloCompagnia
26/02/202522:17Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MIRMMirum Pharmaceuticals Inc
26/02/202522:09Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MIRMMirum Pharmaceuticals Inc
26/02/202522:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRMMirum Pharmaceuticals Inc
26/02/202522:01Business WireMirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
24/02/202514:30Business WireMirum’s CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX)NASDAQ:MIRMMirum Pharmaceuticals Inc
19/02/202522:04Business WireMirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025NASDAQ:MIRMMirum Pharmaceuticals Inc
11/02/202501:00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
04/02/202523:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRMMirum Pharmaceuticals Inc
13/01/202514:30Business WireMirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate UpdatesNASDAQ:MIRMMirum Pharmaceuticals Inc
06/01/202522:04Business WireMirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MIRMMirum Pharmaceuticals Inc
14/11/202414:00Business WireMirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202417:44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202414:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202414:00Business WireMirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
07/11/202422:30Business WireMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:MIRMMirum Pharmaceuticals Inc
04/11/202422:30Business WireMirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
31/10/202413:30Business WireMirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
10/10/202414:30Business WireVolixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary CholangitisNASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202422:01Business WireMirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
31/07/202422:30Business WireMirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
25/07/202414:30Business WireMirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and OlderNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202422:46Business WireApprobation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202422:20Business WireLIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassenNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202414:30Business WireMirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
28/06/202414:30Business WireMirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTXNASDAQ:MIRMMirum Pharmaceuticals Inc
17/06/202414:00Business WireMirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC StudiesNASDAQ:MIRMMirum Pharmaceuticals Inc
16/06/202423:00Business WireMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
07/06/202406:04Business WireLes données à long terme des études LIVMARLI de Mirum sur l’ALGS et la PFIC présentées au congrès de l’EASLNASDAQ:MIRMMirum Pharmaceuticals Inc
07/06/202406:04Business WireLangfristige Daten aus den LIVMARLI-Studien von Mirum bei ALGS und PFIC auf dem EASL-Kongress vorgestelltNASDAQ:MIRMMirum Pharmaceuticals Inc
06/06/202415:30Business WireLong-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL CongressNASDAQ:MIRMMirum Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MIRM

La tua Cronologia

COIN
FYZNFTUSD
Fyooz NFT
BIT
F34766
Vontobel Financial Produ...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci